Climb Bio (NASDAQ:CLYM) Price Target Raised to $32.00

Climb Bio (NASDAQ:CLYM) had its target price increased by BTIG Research from $20.00 to $32.00 in a report published on Thursday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright upped their target price on shares of Climb Bio from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Truist Financial boosted their price target on shares of Climb Bio from $17.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada initiated coverage on shares of Climb Bio in a research report on Monday, August 3rd. They set an “outperform” rating and a $23.00 price target on the stock. Robert W. Baird set a $21.00 price objective on shares of Climb Bio in a research note on Wednesday, May 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 price objective on shares of Climb Bio in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.92.

Climb Bio Stock Performance

Shares of CLYM opened at $15.52 on Thursday. Climb Bio has a one year low of $1.54 and a one year high of $18.33. The stock has a market capitalization of $891.47 million, a price-to-earnings ratio of -18.70 and a beta of 0.09. The stock has a 50 day moving average price of $14.04 and a 200 day moving average price of $10.79.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. On average, analysts predict that Climb Bio will post -0.78 earnings per share for the current year.

Institutional Trading of Climb Bio

A number of hedge funds and other institutional investors have recently modified their holdings of CLYM. Dimensional Fund Advisors LP purchased a new position in shares of Climb Bio during the 1st quarter worth $715,000. Seven Fleet Capital Management LP acquired a new position in shares of Climb Bio during the 4th quarter valued at about $306,000. BlackRock Inc. purchased a new stake in shares of Climb Bio in the second quarter valued at about $30,708,000. ArchPoint Investors purchased a new stake in shares of Climb Bio in the fourth quarter valued at about $486,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Climb Bio during the second quarter worth about $2,148,000. 69.76% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Encouraging CLYM116 data: Climb Bio reported that a single 320 mg dose of CLYM116 produced an approximately 29-day half-life, near-complete APRIL suppression, and 60%–75% reductions in IgA and Gd-IgA1 through 12 weeks. The drug was generally well tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia reported. The data support convenient once-every-12-weeks dosing for IgA nephropathy. Climb Bio CLYM116 Phase 1 Data
• Positive Sentiment: Analyst targets moved substantially higher: B. Riley reaffirmed a Buy rating and raised its price target to $30 from $26. BTIG lifted its target to $32 from $20 and maintained a Buy rating, while Baird raised its target to $25 from $21 and rated the shares Outperform. These revisions indicate analysts see greater commercial and competitive potential for CLYM116.
• Positive Sentiment: Wedbush described the Phase 1 results as positive, while Oppenheimer said the data could demonstrate a competitive position in the IgA nephropathy market. Wedbush Climb Bio Phase 1 Analysis
• Neutral Sentiment: The Phase 2 NAVIGATE-2 trial is ongoing, with initial data expected in the first half of 2027 and a potential Phase 3 start in 2027. Those milestones could provide more meaningful evidence of efficacy, but they also leave significant clinical and execution risk ahead.
• Negative Sentiment: Despite the favorable safety and biomarker results, reports noted that the stock slipped as investors digested the early-stage nature of the data. Phase 1 results do not establish that CLYM116 improves patient outcomes, and the shares’ large prior rally may be encouraging some profit-taking or demanding stronger evidence before advancing further. Climb Bio Slips After Early-Stage Trial Data

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.